Clinical trials
Leukemia, B-cell clinical trials
Below are recruiting leukemia, b-cell clinical trials, each written for real people, not researchers. We’re tracking 273 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06326008RecruitingPhase 1
Donor immune cell therapy for leukemia that returned after treatment
This trial tests a two-step approach using donor immune cells to treat children with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. First, a donor's CD19-targeted cells are given to bridge to a stem cell transplant, followed by CD22-targeted cells to prevent relapse.
Beijing, Beijing MunicipalityAges 1–18 - NCT05672251RecruitingPhase 2
Testing two antibody drugs for lymphoma that came back
This Phase 2 trial tests two targeted antibody medicines—loncastuximab tesirine and mosunetuzumab—in people whose diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma grade 3B has come back or did not respond. It aims to shrink lymphoma that has measurable disease and has specific markers (CD19 and CD20) on tumor cells.
Duarte, CaliforniaAges 18 years+ - NCT06340737RecruitingPhase 1
CD22-targeting CAR T cells for relapsed B cell lymphoma
This trial tests whether giving modified immune cells (CAR T cells) that target CD22 on cancer cells can help people with certain B-cell lymphomas that have come back or not responded to at least two prior treatments. The goal is to see if this approach can shrink tumors or control the disease.
Palo Alto, CaliforniaAges 18 years+ - NCT06343090Recruiting
Comparing two CAR T cell treatments for children and adults with B-ALL
This trial tests whether giving two types of CAR T cells (CD19 and CD22) one after the other works better than giving just one type (CD19) followed by a stem cell transplant for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or not gone away. The goal is to see which approach offers a better chance of long-term remission.
Beijing, Beijing MunicipalityAges 1–70 - NCT06343311RecruitingPhase 1/Phase 2
T-cell therapy for adults with relapsed or refractory B-cell lymphoma
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
Sacramento, CaliforniaAges 18 years+ - NCT06350994Recruiting
Early Heart Check After CAR-T Cell Treatment
This study checks your heart function early after CAR-T cell cancer treatment. It uses a quick heart ultrasound to look for changes soon after the infusion.
ParisAges 18 years+ - NCT06355739Recruiting
CAR T cells for children with relapsed B-cell leukemia
This trial tests whether giving you a special kind of immune cell, called a CAR T cell, can help fight your B-cell leukemia or lymphoma that has come back or not gone away with standard treatments. The cells are made from your own blood and designed to attack the cancer cells that carry a marker called CD19.
Tianjin, Tianjin MunicipalityAges 3–18 - NCT06364423RecruitingPhase 1/Phase 2
CAR T-cell therapy for CD19-positive leukemias and lymphomas
This trial tests a new immune therapy that uses your own cells (CAR T-cells) to find and attack cancer cells with the CD19 protein. It is for people with certain types of leukemia or lymphoma that have not responded to other treatments.
Bethesda, MarylandAges 18–120 - NCT06389305Recruiting
CIK cell therapy for B-cell leukemia after CAR-T failure
This trial tests CIK immune cells for children and young adults with B-cell acute lymphoblastic leukemia that stopped responding to CAR-T cell therapy within 6 months. The goal is to see if CIK cells can help when CAR-T cells no longer work.
Beijing, Beijing MunicipalityAges 1–39 - NCT06393985RecruitingPhase 2
Maintenance therapy after stem cell transplant for B-ALL
This trial tests whether three targeted medicines (decitabine, venetoclax, and blinatumomab) can help prevent leukemia from coming back after a stem cell transplant. It is for people with B-cell ALL who have no detectable remaining leukemia cells and are at least 3 months past transplant.
Suzhou, JiangsuAges 18–65 - NCT06415708RecruitingPhase 2
Obinutuzumab with bendamustine for B-cell lymphoma
This trial tests a combination of two drugs—obinutuzumab and bendamustine—for people with certain B-cell lymphomas that haven't been treated before. The goal is to see how well this combination works and how safe it is.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06445803RecruitingPhase 1
CAR-T therapy for adults with certain blood cancers
This trial tests a type of immunotherapy called CAR-T cells that target two proteins (CD19 and CD22) on cancer cells. It may be an option for adults with B-cell acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL) that has come back or not responded to earlier treatments.
Nanchang, JiangxiAges 18 years+ - NCT06450067Recruiting
Inaticabtagene Autoleucel for Relapsed or Refractory ALL
This trial tests a personalized cell therapy for adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It may offer a new option for people who need additional treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06462248RecruitingPhase 2
CAR-T therapy for B-cell blood cancers
This trial tests a new CAR-T cell therapy that targets a protein called CD19 on B-cell cancer cells. It is for children and adults with B-cell acute lymphoblastic leukemia or certain B-cell lymphomas that have not improved with standard treatments.
Hong KongAges 1 year+ - NCT06462365RecruitingPhase 1
Preventing GvHD after stem cell transplant for blood cancers
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
Duarte, CaliforniaAges 18 years+ - NCT06503094RecruitingPhase 1/Phase 2
CAR T cells targeting CD19 and CD20 for relapsed B-cell cancers
This trial tests a new type of CAR T-cell therapy that targets two markers (CD19 and CD20) on B-cell cancer cells. It is for people whose B-cell leukemia or lymphoma has come back or not responded to standard treatments.
Wuhan, HubeiAges 14–75 - NCT06507514RecruitingPhase 1
Blinatumomab with stem cell transplant for B-ALL
This trial tests a treatment plan that uses blinatumomab (a drug that helps your immune system attack leukemia cells) combined with your own stem cell transplant. It is for people with B-ALL who cannot or choose not to have a transplant from another person.
Suzhou, JiangsuAges 15–65 - NCT06508931RecruitingPhase 2
Zamtocabtagene autoleucel for children with B-cell lymphoma or leukemia
This trial tests a new CAR T-cell therapy (zamtocabtagene autoleucel) for children and teens whose B-cell lymphoma or leukemia has come back or hasn't responded to other treatments. The goal is to see if this one-time infusion can help their immune system fight the cancer.
Paris, Boulevard Sérurier 48Ages 6 months–17 years - NCT06514768RecruitingEarly Phase 1
JY231 injection for B-cell acute lymphoblastic leukemia
This trial tests a new injection (JY231) for people with B-cell acute lymphoblastic leukemia (B-ALL) that has not responded well to treatment or has come back. It aims to see if the treatment can help reduce cancer cells in the bone marrow.
Kunming, YunnanAges Up to 75 years - NCT06528301RecruitingPhase 1
Trial of UB-VV111 with or without rapamycin for B-cell cancers
This trial tests a new therapy called UB-VV111, alone or with rapamycin, in people with certain types of lymphoma or leukemia that have come back or not responded to treatment. The goal is to see if it's safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06536049RecruitingPhase 1/Phase 2
Epcoritamab plus ibrutinib for relapsed or refractory aggressive B-cell lymphoma
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
Minneapolis, MinnesotaAges 18 years+ - NCT06536452Recruiting
How blood cell production differs in CLL, MBL, and healthy people
This trial studies how the body makes blood cells in people with chronic lymphocytic leukemia (CLL), a related condition called monoclonal B-cell lymphocytosis (MBL), and in healthy volunteers matched by age. The goal is to understand differences that may help improve treatment or monitoring.
Rochester, MinnesotaAges 40 years+ - NCT06554626RecruitingPhase 2
Study of blinatumomab and venetoclax followed by inotuzumab for B-ALL
This trial tests a sequence of three drugs for adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome. The goal is to see if this approach can better treat the leukemia.
Hangzhou, ZhejiangAges 40 years+ - NCT06559189RecruitingPhase 1
A new CAR T therapy for children with relapsed B-ALL
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
Aurora, ColoradoAges 3 months–30 years
Hear when a new Leukemia, B-cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia, b-cell?
- Yes. Clin2 currently lists 273 recruiting leukemia, b-cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia, b-cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia, b-cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.